Which impact has Bempedoic Acid on atherosclrosis plaque stability ?

Atherosclerosis is the pathophysiologic mechanism for ischemic heart disease. Modern advances in managing cardiovascular disease and the introduction of percutaneous coronary intervention and the use of stent have reduced the mortality of this disease. However, lipid-lowering therapy has been the mainstay of cardiovascular risk reduction and prevention, with statins significantly reducing serum cholesterol and stabilizing atherosclerotic plaque. Bempedoic acid (BDA) is a non-statin antihyperlipidemic drug developed by Esperion Therapeutics to treat hypercholesterolemia. It showed promising results in phase III CLEAR clinical trial program; thus, BDA has been used as monotherapy and in combination with ezetimibe in both the United States and European Union. CAD is a fatal disease that can be prevented with proper diet and lifestyle modification. Many clinicians face challenges despite adequate measures taken to lower the main culprit for atherosclerosis formation, i.e., LDL-C, which remains high in some patients despite being on maximally tolerated statin regimens. A recent systematic review conducted on 11 articles to find new evidence on the role of BDA as secondary drug therapy for patients who are on maximally tolerated statins or statin intolerant. Although at the moment, BDA has shown significant LDL-C lowering effects, both alone and in combination with ezetimibe, there is reported evidence of some side effects in selected patients. More data will be available after CLEAR Outcome results are available which will further enlighten us about the safety and efficacy of BDA. Further research and trials are needed to significantly conclude the more positive role of BDA in lowering serum LDL-C and preventing cardiovascular events in clinical practice, particularly for patients with CAD or coronary heart disease. 

Bempedoic acid is mechanistically linked to plaque stabilization, primarily through combined LDL-C lowering and anti-inflammatory effects. Beyond hepatic ATP-citrate lyase inhibition, bempedoic acid activates AMPK signaling, which suppresses vascular inflammatory pathways (e.g., MAPK-mediated cytokine and adhesion molecule expression).
Preclinical data summarized in recent reviews demonstrate that liver-specific ACLY inhibition attenuates atherosclerotic lesion development and reduces macrophage-driven inflammation, mechanisms consistent with improved plaque stability. Clinically, sustained reductions in hsCRP (~20–30%) further support an anti-inflammatory, plaque-protective profile.
However, direct human imaging evidence confirming changes in plaque composition or fibrous cap thickness (IVUS/OCT/CCTA) remains limited. Thus, current evidence supports biological plausibility and indirect stabilization, with definitive confirmation awaiting dedicated plaque-imaging studies.

This is a great question, and I'm really excited about it. One way to think about how bempedoic acid affects plaque is as a strong one-two punch.
First of all, it does the obvious job very well. It was smartly made so that it only works in the liver, where it strongly lowers LDL cholesterol, which is the "bad" cholesterol. For decades, we've known that lowering LDL levels aggressively is important. It takes away the fuel that the plaque needs to grow, which makes it smaller and more stable over time. That's the main benefit.
But here's the most interesting part: it also seems to put out the fire.
The big clinical trials show that it lowers inflammation markers like hs-CRP a lot, and this isn't just because it lowers cholesterol. The idea is that by hitting its target enzyme (ACL), it also cuts off the resources that inflammatory cells in the plaque need to stay "angry" and do damage. It helps calm everything down, which makes it less likely that the plaque will break.
So, even though we are still waiting for direct human imaging to show us this happening in real time, the evidence is strong. The lower number of heart attacks isn't just because of better numbers; it looks like the drug is changing the plaque itself.
In short, it takes away the fuel (LDL) and puts out the fire that causes inflammation. That's a strong mix for keeping plaque stable and what makes it such an intriguing drug.